“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.
|Articles|October 1, 1998
Oncology NEWS International
- Oncology NEWS International Vol 7 No 10
- Volume 7
- Issue 10
NCI Seeks New Technologies
BETHESDA, Md--The National Cancer Institute (NCI) is seeking technology systems to revolutionize cancer detection, diagnosis, and treatment. Under a new $48 million, 5-year program dubbed the Unconventional Innovations Program, NCI is looking for new technologies "that will enable sensing of molecular alterations in the body in a way that is highly sensitive and specific, yet nonintrusive."
Advertisement
BETHESDA, Md--The National Cancer Institute (NCI) is seeking technology systems to revolutionize cancer detection, diagnosis, and treatment. Under a new $48 million, 5-year program dubbed the Unconventional Innovations Program, NCI is looking for new technologies "that will enable sensing of molecular alterations in the body in a way that is highly sensitive and specific, yet nonintrusive."
NCI has requested input from molecular and cellular biologists, engineers, physicists, chemists, and computational biologists who can point to new directions for research. Information obtained will be used to outline government research goals that will be issued in late 1998 or early 1999, followed by requests for specific research proposals.
Articles in this issue
about 28 years ago
Panel Recommends Photofrin for Use in Late-Stage Lung Cancerabout 28 years ago
California Intervention Raises Consumption of Fruits and Vegetablesabout 28 years ago
ODAC Panel Okays Nolvadex to Reduce Breast Cancer Riskabout 28 years ago
Evolving Role for Preoperative Chemo in Breast Cancerabout 28 years ago
NCI Sets Sail on a New Tack In the Stormy Seas of CAMabout 28 years ago
Opioid Antagonists Can Control Opioid-Induced Constipationabout 28 years ago
NIAID Collaborates With VaxGen, Inc. on Trials of AIDSVAXabout 28 years ago
Clinicians Often Fail To Provide Adequate Genetic Counselingabout 28 years ago
Networks Assist Community Oncologists in Research QuestAdvertisement
Related to this article
Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases.
Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.
Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.
Adjuvant radiotherapy significantly reduced meningioma recurrence or death vs observation in grade 2 atypical meningioma after complete surgical resection.
VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, showed an 82% PSA50 response rate and 45% ORR at higher doses in heavily pretreated mCRPC.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
How Emory Became the First Adopter of the Liberty Endovascular Robotic System
3
Building out a Radiopharmaceuticals Program in Oncology Care
4
Rinatabart Sesutecan Elicits Responses in PROC Regardless of FRα Expression
5